Official Title: “Pioglitazone and Exercise Effects on Older Adults With MCI and Metabolic Syndrome”

The purpose of this study is to investigate novel treatments to delay progression to dementia in patients with mild cognitive impairment (MCI) and metabolic syndrome (MS). The hypothesis is that treatment with pioglitazone or endurance exercise training will improve, stabilize, or attenuate decline in cognitive function compared to controls. This study will also discover potential mechanisms for the improvements and determine the baseline prevalence of amnestic versus non-amnestic MCI.

Study Type: Interventional

Study Design: Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study

Study Primary Completion Date: August 2011

The Metabolic Syndrome (MS) is a rapidly growing public health problem. This constellation of metabolic abnormalities increases the risk of diabetes, heart disease and death. Recently evidence has linked MS with cognitive impairment and dementia, including Alzheimer's Disease (AD). AD is preceded by a state called Mild Cognitive Impairment (MCI), characterized by subjective and objective memory impairment, but no functional impairment. Although not all persons with MCI will develop AD, the conversion rate from MCI to AD is about 15% per year, or 5-10 times that of cognitively normal individuals.

There is great interest in finding treatments to prevent AD by intervening at an earlier stage, i.e. MCI.

The mechanism(s) linking MS and cognitive impairment are not clear, although there is evidence that insulin resistance and inflammation play key roles.

Thiazolidinediones (TZDs) are medications approved for the treatment of Type 2 Diabetes, which work by reducing insulin resistance. In addition, these drugs have anti-inflammatory properties. A recent pilot study showed improvements in some areas of cognition in patients with MCI or mild AD treated with the TZD rosiglitazone. Endurance exercise training (EET) is an established treatment for MS and insulin resistance. There is also evidence that EET may improve cognitive function as well.

Adults aged 55 years or older with both MS and MCI at baseline will be randomized to a 6-month intervention with either (1) treatment with pioglitazone, (2) endurance exercise training, or (3) control (placebo and no exercise). The hypothesis is that treatment with the TZD pioglitazone or EET will improve cognitive function compared to controls, as evidenced by either improvement, stabilization, or lesser decline in performance on cognitive testing.

Participants will undergo a physical exam including blood and urine tests, a complete neurologic exam, and a comprehensive battery of cognitive tests.

They will also have a DEXA scan, exercise treadmill test, non-invasive tests of vascular function and a hyperglycemic-euglycemic clamp procedure to measure insulin resistance.

Intervention(s) in this Clinical Trial

• Drug: Pioglitazone
  • 30 - 45mg tablet daily for 6 months
• Drug: Placebo
  • Matching tablet daily for 6 months
• Behavioral: Endurance Exercise Training (EET)
  • Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: Pioglitazone
• Active Comparator: EET
• Placebo Comparator: Placebo

Primary Measures

• Changes in cognitive performance on tests of (1) Memory, (2) Language, (3) Attention/Executive Function, and (4) Visuospatial Function
  • Time Frame: baseline and 6 months
    Safety Issue?: No

Secondary Measures

• Insulin resistance, measured by the hyperglycemic-euglycemic clamp procedure, and whether any improvements are correlated with corresponding improvements in cognition
  • Time Frame: baseline and at 6 months
    Safety Issue?: No

Inclusion Criteria:

• Community-dwelling, over 55 years old, able to give full informed consent, willing to be randomized
• Able to perform a telephone interview
• Able to speak, read and understand English
• Potential volunteers on a statin drug, angiotensin converting enzyme inhibitor (ACE-I), angiotensin II receptor blocker (ARB), non-steroidal anti-inflammatory drug (NSAID), or Vitamin E supplement, are eligible but must be on a stable dose for at least 2 months
• Women must be post-menopausal, as defined by no menses for 12 months
• Must meet 3 of the 5 requirements for Metabolic Syndrome:
• Waist measurement: greater than 102 cm for men and 88 cm for women
• Fasting hypertriglyceridemia: 150 mg/dl (1.7 mmol/L) or higher
• Low HDL cholesterol: less than 40 mg/dl (1.0 mmol/L) for men and 50 mg/dl (1.3 mmol/L) for women
• Hypertension: higher than 130 mmHg systolic or 85 mmHg diastolic (average of 2 seated measurements) or currently using an antihypertensive medication
• Elevated (untreated) fasting glucose: 100 mg/dl (5.6 mmol/L) or higher
• Meet the study's 4-step screening process for MCI (to rule out dementia)

Exclusion Criteria:

• Diagnosis of diabetes mellitus (DM), defined as: Fasting Blood Sugar 126 or higher, a history of known DM, or treatment with any glucose lowering medication
• Current diagnosis of dementia (or MMSE less than 24) or a neurological co-morbidity other than MCI that might affect cognition including: large vessel stroke, brain tumor, severe brain injury, multiple sclerosis, or Parkinson's disease
• Current diagnosis of depression assessed by a Centers for Epidemiologic Studies
• Depression Scale (CES-D) score of 36 or less
• Major psychiatric conditions such as bipolar disorder, psychosis, schizophrenia, or alcoholism that could affect the ability to understand and/or cooperate fully with the protocol
• Significant cerebral vascular disease
• Modified Hachinski score greater than 4
• Pregnant, lactating or having child bearing potential
• Concomitant medications with significant cholinergic or anticholinergic effects or adverse effects on cognition including: antipsychotics, tricyclic antidepressants, anticonvulsants, sedative/hypnotics, anxiolytics, glucocorticoids (chronic or frequent intermittent), gingko biloba, NMDA receptor antagonists, cholinesterase inhibitors, strongly lipid soluble beta blockers (e.g., propranolol)
• Hormone replacement therapy (male or female)
• Visual/hearing impairment that would significantly impact the ability to undergo psychometric testing
• Significant medical illness or organ failure including hepatic or renal failure, unstable cardiac disease, or life expectancy less than 18 months
• Exercise-limiting conditions including: neuromuscular, joint/bone, cardiovascular, peripheral vascular, cerebrovascular or pulmonary disease; recent MI, pulmonary embolus, significant aortic stenosis; or exercise limiting obesity
• Untreated B12 deficiency or hypothyroidism (stable treatment for at least 3 months is allowable)
• Uncontrolled hypertension: over 160 mmHg systolic or 100 mmHg diastolic (stable treatment is allowable)
• Endurance exercise training more than twice a week for 20 minutes (at a level that produces sweating) consistently during the last 6 months
• Unstable weight in the last 6 months
• Increased risk for Pio toxicity including: a) baseline liver dysfunction (over 2.5xULN for AST, ALT); b) hematocrit less than 33% men or 30% women; c) problematic edema; or d) congestive heart failure NYHA class II or greater
• Stage 5 renal impairment (GFR less than 15 or dialysis)
• Already taking a TZD or other drug that would modify insulin resistance (e.g.
• metformin), or has taken a TZD in the past and experienced a significant adverse effect or allergy
• Currently taking any of following medications that may interact with Pio metabolism: atorvastatin at 80mg/day (lower doses are allowed), and medications with major CYP 3A4 inhibiting effects, such as nefazodone or systemic antifungal agents
• Participating in another clinical trial

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 55 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Lead Sponsor: National Institute on Aging (NIA)

Overall Clinical Trial Officials and Contacts

Robert S. Schwartz, MD Principal Investigator University of Colorado Denver  

Overall Contact: Erica Borresen, BS 720-848-6376 erica.borresen@uchsc.edu

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00736996

Study ID Number: IA0137

ClinicalTrials.gov Identifier: NCT00736996

Health Authority: United States: Federal Government